Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma.

CD155 is frequently overexpressed in human malignant tumors, and it is associated with poor prognosis. The expression of its soluble form (sCD155) as well as its prognostic value were not studied previously in diffuse large B cell lymphoma (DLBCL). Serum sCD155 level was measured in DLBCL patients at diagnosis using enzyme-linked immunosorbent assay. Its impact on response following three cycles of CHOP with or without rituximab (CHOP ± R) was analyzed. Serum sCD155 level was significantly elevated in DLBCL patients at diagnosis than in controls (P < 0.001). Serum sCD155 level at diagnosis correlated significantly with International Prognostic Index risk score (P = 0.005). Elevated serum sCD155 was associated with lack of response following three cycles of CHOP ± R in univariate analysis (P = 0.003). On multivariate analysis, there was a 1.601 probability of lack of response in patients with increased sCD155 level (95% confidence interval = 0.774-3.309, P = 0.204). Serum sCD155 is overexpressed in DLBCL, and it is associated with lack of interim response to CHOP ± R.